Pheton (PTHL) Competitors

$0.31 +0.01 (+3.43%)

As of 05/22/2026

PTHL vs. CODX, NDRA, NVNO, NXL, and PAVM

Should you buy Pheton stock or one of its competitors? MarketBeat compares Pheton with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pheton include Co-Diagnostics (CODX), ENDRA Life Sciences (NDRA), enVVeno Medical (NVNO), Nexalin Technology (NXL), and PAVmed (PAVM). These companies are all part of the "medical equipment" industry.

How does Pheton compare to Co-Diagnostics?

Co-Diagnostics (NASDAQ:CODX) and Pheton (NASDAQ:PTHL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

Pheton has a net margin of 0.00% compared to Co-Diagnostics' net margin of -6,760.63%. Pheton's return on equity of 0.00% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-6,760.63%	-164.92%	-141.15%
Pheton	N/A	N/A	N/A

In the previous week, Co-Diagnostics had 6 more articles in the media than Pheton. MarketBeat recorded 7 mentions for Co-Diagnostics and 1 mentions for Pheton. Co-Diagnostics' average media sentiment score of 0.05 beat Pheton's score of 0.00 indicating that Co-Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Co-Diagnostics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pheton	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Co-Diagnostics presently has a consensus price target of $67.50, suggesting a potential upside of 1,231.36%. Given Co-Diagnostics' stronger consensus rating and higher probable upside, research analysts plainly believe Co-Diagnostics is more favorable than Pheton.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pheton	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Pheton has lower revenue, but higher earnings than Co-Diagnostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$620K	29.44	-$46.90M	-$15.77	N/A
Pheton	$305.22K	6.71	-$660K	N/A	N/A

15.0% of Co-Diagnostics shares are owned by institutional investors. 5.4% of Co-Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Co-Diagnostics has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, Pheton has a beta of 5.4, indicating that its stock price is 440% more volatile than the broader market.

Summary

Co-Diagnostics beats Pheton on 9 of the 14 factors compared between the two stocks.

How does Pheton compare to ENDRA Life Sciences?

ENDRA Life Sciences (NASDAQ:NDRA) and Pheton (NASDAQ:PTHL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

In the previous week, Pheton had 1 more articles in the media than ENDRA Life Sciences. MarketBeat recorded 1 mentions for Pheton and 0 mentions for ENDRA Life Sciences. ENDRA Life Sciences' average media sentiment score of 0.00 equaled Pheton'saverage media sentiment score.

Company	Overall Sentiment
ENDRA Life Sciences	Neutral
Pheton	Neutral

1.2% of ENDRA Life Sciences shares are owned by institutional investors. 10.0% of ENDRA Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

ENDRA Life Sciences has a beta of -0.11, suggesting that its share price is 111% less volatile than the broader market. Comparatively, Pheton has a beta of 5.4, suggesting that its share price is 440% more volatile than the broader market.

ENDRA Life Sciences currently has a consensus price target of $30.00, suggesting a potential upside of 435.71%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe ENDRA Life Sciences is more favorable than Pheton.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pheton	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Pheton has higher revenue and earnings than ENDRA Life Sciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$8.15	N/A
Pheton	$305.22K	6.71	-$660K	N/A	N/A

Pheton's return on equity of 0.00% beat ENDRA Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ENDRA Life Sciences	N/A	-433.64%	-204.58%
Pheton	N/A	N/A	N/A

Summary

Pheton beats ENDRA Life Sciences on 6 of the 11 factors compared between the two stocks.

How does Pheton compare to enVVeno Medical?

Pheton (NASDAQ:PTHL) and enVVeno Medical (NASDAQ:NVNO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Pheton has higher revenue and earnings than enVVeno Medical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pheton	$305.22K	6.71	-$660K	N/A	N/A
enVVeno Medical	N/A	N/A	-$19.47M	-$25.54	N/A

Pheton has a beta of 5.4, meaning that its stock price is 440% more volatile than the broader market. Comparatively, enVVeno Medical has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market.

Pheton's return on equity of 0.00% beat enVVeno Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pheton	N/A	N/A	N/A
enVVeno Medical	N/A	-66.39%	-60.42%

In the previous week, Pheton had 1 more articles in the media than enVVeno Medical. MarketBeat recorded 1 mentions for Pheton and 0 mentions for enVVeno Medical. Pheton's average media sentiment score of 0.00 equaled enVVeno Medical'saverage media sentiment score.

Company	Overall Sentiment
Pheton	Neutral
enVVeno Medical	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pheton	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
enVVeno Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

34.7% of enVVeno Medical shares are owned by institutional investors. 15.0% of enVVeno Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Pheton beats enVVeno Medical on 6 of the 9 factors compared between the two stocks.

How does Pheton compare to Nexalin Technology?

Nexalin Technology (NASDAQ:NXL) and Pheton (NASDAQ:PTHL) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

0.7% of Nexalin Technology shares are held by institutional investors. 25.3% of Nexalin Technology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Nexalin Technology has a beta of 3.56, suggesting that its share price is 256% more volatile than the broader market. Comparatively, Pheton has a beta of 5.4, suggesting that its share price is 440% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pheton	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Nexalin Technology had 2 more articles in the media than Pheton. MarketBeat recorded 3 mentions for Nexalin Technology and 1 mentions for Pheton. Nexalin Technology's average media sentiment score of 0.36 beat Pheton's score of 0.00 indicating that Nexalin Technology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nexalin Technology	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pheton	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pheton has a net margin of 0.00% compared to Nexalin Technology's net margin of -3,018.12%. Pheton's return on equity of 0.00% beat Nexalin Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-3,018.12%	-191.88%	-166.43%
Pheton	N/A	N/A	N/A

Pheton has higher revenue and earnings than Nexalin Technology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$300K	25.91	-$8.22M	-$0.47	N/A
Pheton	$305.22K	6.71	-$660K	N/A	N/A

Summary

Pheton beats Nexalin Technology on 6 of the 11 factors compared between the two stocks.

How does Pheton compare to PAVmed?

PAVmed (NASDAQ:PAVM) and Pheton (NASDAQ:PTHL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

PAVmed has higher earnings, but lower revenue than Pheton.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PAVmed	$70K	91.29	$400K	-$37.40	N/A
Pheton	$305.22K	6.71	-$660K	N/A	N/A

19.9% of PAVmed shares are held by institutional investors. 13.4% of PAVmed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, PAVmed and PAVmed both had 1 articles in the media. PAVmed's average media sentiment score of 0.00 equaled Pheton'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PAVmed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pheton	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PAVmed presently has a consensus target price of $65.00, indicating a potential upside of 917.21%. Given PAVmed's stronger consensus rating and higher probable upside, analysts plainly believe PAVmed is more favorable than Pheton.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pheton	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PAVmed has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market. Comparatively, Pheton has a beta of 5.4, suggesting that its share price is 440% more volatile than the broader market.

Pheton has a net margin of 0.00% compared to PAVmed's net margin of -21,914.12%. Pheton's return on equity of 0.00% beat PAVmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PAVmed	-21,914.12%	-146.19%	-18.39%
Pheton	N/A	N/A	N/A

Summary

PAVmed beats Pheton on 7 of the 12 factors compared between the two stocks.

Get Pheton News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTHL vs. The Competition

Export

Metric	Pheton	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.05M	$8.38B	$6.46B	$12.34B
Dividend Yield	N/A	2.98%	2.76%	5.28%
P/E Ratio	N/A	21.27	20.99	25.66
Price / Sales	6.71	19.11	559.58	86.31
Price / Cash	N/A	86.20	43.49	56.67
Price / Book	0.33	5.84	10.44	7.14
Net Income	-$660K	$183.47M	$3.57B	$335.98M
7 Day Performance	2.30%	64.18%	6.37%	4.11%
1 Month Performance	-16.84%	49.96%	3.51%	2.52%
1 Year Performance	-95.28%	4.53%	34.10%	35.04%

Pheton Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTHL Pheton	N/A	$0.31 +3.4%	N/A	-95.3%	$2.05M	$305.22K	N/A	11
CODX Co-Diagnostics	1.956 of 5 stars	$2.39 +21.3%	$67.50 +2,724.3%	-27.0%	$7.10M	$620K	N/A	100	Analyst Upgrade Gap Down High Trading Volume
NDRA ENDRA Life Sciences	2.3228 of 5 stars	$5.55 -0.7%	$30.00 +440.5%	+80.1%	$7.10M	N/A	N/A	20
NVNO enVVeno Medical	0.7523 of 5 stars	$10.95 +7.9%	N/A	-90.9%	$6.78M	N/A	N/A	30
NXL Nexalin Technology	0.6548 of 5 stars	$0.34 +4.4%	N/A	-69.3%	$6.61M	$300K	N/A	3

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTHL) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pheton (PTHL) Competitors

PTHL vs. CODX, NDRA, NVNO, NXL, and PAVM

How does Pheton compare to Co-Diagnostics?

Summary

How does Pheton compare to ENDRA Life Sciences?

Summary

How does Pheton compare to enVVeno Medical?

Summary

How does Pheton compare to Nexalin Technology?

Summary

How does Pheton compare to PAVmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTHL vs. The Competition

Pheton Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pheton (PTHL) Competitors

PTHL vs. CODX, NDRA, NVNO, NXL, and PAVM

How does Pheton compare to Co-Diagnostics?

Is CODX or PTHL more profitable?

Does the media prefer CODX or PTHL?

Do analysts rate CODX or PTHL?

Which has higher earnings & valuation, CODX or PTHL?

Do insiders and institutionals have more ownership in CODX or PTHL?

Which has more volatility and risk, CODX or PTHL?

Summary

How does Pheton compare to ENDRA Life Sciences?

Does the media prefer NDRA or PTHL?

Do institutionals and insiders have more ownership in NDRA or PTHL?

Which has more risk and volatility, NDRA or PTHL?

Do analysts rate NDRA or PTHL?

Which has stronger earnings and valuation, NDRA or PTHL?

Is NDRA or PTHL more profitable?

Summary

How does Pheton compare to enVVeno Medical?

Which has preferable earnings & valuation, PTHL or NVNO?

Which has more volatility and risk, PTHL or NVNO?

Is PTHL or NVNO more profitable?

Does the media refer more to PTHL or NVNO?

Do analysts rate PTHL or NVNO?

Do insiders and institutionals hold more shares of PTHL or NVNO?

Summary

How does Pheton compare to Nexalin Technology?

Do institutionals and insiders have more ownership in NXL or PTHL?

Which has more risk and volatility, NXL or PTHL?

Do analysts recommend NXL or PTHL?

Does the media favor NXL or PTHL?

Is NXL or PTHL more profitable?

Which has stronger valuation & earnings, NXL or PTHL?

Summary

How does Pheton compare to PAVmed?

Which has preferable earnings & valuation, PAVM or PTHL?

Do insiders and institutionals believe in PAVM or PTHL?

Does the media prefer PAVM or PTHL?

Do analysts rate PAVM or PTHL?

Which has more volatility and risk, PAVM or PTHL?

Is PAVM or PTHL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTHL vs. The Competition

Pheton Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools